Plasma microRNA signatures to predict EGFR-TKI resistance in EGFR-mutant advanced NSCLC patients.

被引：0
|
作者：
Wang, Shuhang
Wang, Jie
Bai, Hua
An, Tongtong
Zhao, Jun
Wang, Zhijie
Duan, Jianchun
Zhuo, Minglei
Wang, Yuyan
Wu, Meina
机构：
[1] Beijing Canc Hosp, Minist Educ, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China
[2] Peking Univ, Canc Hosp, Sch Oncol, Beijing Canc Hosp, Beijing 100871, Peoples R China
[3] Peking Univ, Sch Oncol, Beijing Canc Hosp & Inst, Beijing 100871, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19136
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
    Yu, Helena A.
    Arcila, Maria E.
    Rekhtman, Natasha
    Sima, Camelia S.
    Zakowski, Maureen F.
    Pao, William
    Kris, Mark G.
    Miller, Vincent A.
    Ladanyi, Marc
    Riely, Gregory J.
    [J]. CLINICAL CANCER RESEARCH, 2013, 19 (08) : 2240 - 2247
  • [32] Continuous Vaginal Bleeding Induced By EGFR-TKI in Premenopausal Female Patients With EGFR Mutant NSCLC
    Yu, Min
    Li, Xiaoyu
    Wu, Xueqian
    Wang, Weiya
    Li, Yanying
    Zhang, Yan
    Zhang, Shuang
    Wang, Yongsheng
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [33] Radiographic patterns of progression in patients with EGFR-mutant NSCLC undergoing EGFR TKI therapy.
    Brenner, Nicole
    Bastos, Bruno R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [34] The clinical utility of longitudinal measurement of mutated EGFR in plasma of advanced NSCLC patients during EGFR-TKI treatment
    Szpechcinski, A.
    Bryl, M.
    Wojda, E.
    Czyzewicz, G.
    Swiniuch, D.
    Szwiec, M.
    Ramlau, R.
    Sliwinski, P.
    Barinow-Wojewodzki, A.
    Chorostowska-Wynimko, J.
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [35] Sintilimab ± IBI305 Plus Chemotherapy for Patients With EGFR-Mutant Non-Squamous NSCLC Failed to EGFR-TKI Treatment
    Lu, S.
    Cheng, Y.
    Wu, L.
    Fang, J.
    Li, B.
    Han, L.
    Zhang, Y.
    Pan, H.
    Wang, Z.
    Sun, Y.
    Ye, F.
    Hu, Y.
    Yu, W.
    Zhou, H.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S649 - S649
  • [36] T790M MUTATION ASSOCIATED WITH BETTER EFFICACY OF CONTINUOUS EGFR-TKI TREATMENT IN ADVANCED NSCLC PATIENTS WITH ACQUIRED RESISTANCE TO EGFR-TKI
    Ren, Shengxiang
    Li, Wei
    Li, Aiwu
    Chen, Xiaoxia
    Gao, Guanghui
    He, Yayi
    Li, Xuefei
    Zhou, Caicun
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1084 - S1084
  • [37] Neoadjuvant EGFR-TKI Therapy for EGFR-Mutant NSCLC: A Systematic Review and Pooled Analysis of Five Prospective Clinical Trials
    Sun, Li
    Guo, Yi-Jia
    Song, Jun
    Wang, Yan-Ru
    Zhang, Shu-Ling
    Huang, Le-Tian
    Zhao, Jian-Zhu
    Jing, Wei
    Han, Cheng-Bo
    Ma, Jie-Tao
    [J]. FRONTIERS IN ONCOLOGY, 2021, 10
  • [38] First-Line Continual EGFR-TKI Plus LAT Demonstrated Survival Benefit in Egfr-Mutant Nsclc Patients with Oligoprogressive Disease
    Xu, Q.
    Liu, H.
    Hang, T.
    Ren, S.
    Zhou, C.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S592 - S592
  • [39] The Predictive Factors for Post-Progression Survival after EGFR-TKI Failure in Advanced EGFR-Mutant Lung Cancer Patients
    Ebisudani, Toshiki
    Nakashima, Kei
    Misawa, Masafumi
    Tokumoto, Akiko
    Nemoto, Masahiro
    Tsuzuki, Ryuta
    Suzuki, Fumi
    Yamawaki, Satoshi
    Otsuki, Ayumu
    Noma, Satoshi
    Aoshima, Masahiro
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1208 - S1209
  • [40] The IASLC Grading System as a Predictor For EGFR-TKI Therapy in EGFR-Mutant Lung Adenocarcinoma
    Deng, C.
    Chen, H.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S175 - S175
12345